

Strategic Transaction Positions Veracyte to Become a Premier Global Diagnostics Company

December 3, 2019

® Veracyte, Inc. All rights reserved. CONFIDENTIAL

Forward-Looking Statements

This presentation contains statements that are not historical and that are based on our beliefs and assumptions and on information currently available to us. These statements constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from our expectations.

Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the asset acquisition from NanoString Technologies, Inc.; our revenue, market and operational expectations for the nCounter platform and the Prosigna and LymphMark tests; our ability to successfully integrate the acquired assets into our current business; our expectations regarding future revenues and margins, as well as our expectations regarding our year-end performance; our ability to achieve and maintain Medicare coverage for our tests; the benefits of our tests and the applicability of clinical results to actual outcomes; the size of our addressable market; the laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our ability to successfully maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the continued application of clinical guidelines to our products and their inclusion in such clinical practice guidelines; our ability to compete; our ability to obtain capital when needed; and other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.

Veracyte, Afirma, Percepta, Envisia, Know by Design, the Veracyte logo and Afirma logo are trademarks of Veracyte, Inc. This presentation also contains trademarks and trade names that are the property of their respective owners

Transaction Leverages Best-In-Class Capabilities



Leader in developing & commercializing high-value genomic diagnostics



World-class technology & platform for genomic diagnostics

nCounter® FLEX Analysis System





What are the Components of the Transaction?

Exclusive Global Diagnostics Rights to nCounter FLEX Analysis System

Simultaneous multiplex testing of up to 800 RNA, DNA and protein targets

Elegantly simple, kit-enabled platform

>80% reduction in hands-on time versus sequencing



Global Sales, Marketing & Distribution Infrastructure

Presence in 22 countries

Hundreds of installed systems

Distribution agreements

Key personnel & expertise

Long-term supply & service agreements

Products to Expand Oncology Indications





Transaction Powers Veracyte Strategic Transformation

Premier Global Diagnostics Company



Global Market Access



Menu Expansion & Pipeline Development



/†e"



veracy


nCounter System Diagnostic Assets TELLOSON !!

Enhanced Biopharma Partnership Capabilities



Potential for Long-term Revenue Growth & Margin Expansion


Current Veracyte U.S. Test Menu



* Midpoint of 2019 guidance range of \$119 million to \$122 million as of October 22, 2019.

® Veracyte, Inc. All rights reserved. CONFIDENTIAL

2020: Global Market Access and Expanded U.S. Test Menu



2-3 Years: Global Menu Expansion

U.S.:

• Nasal Swab Classifier (2021)

veracyte.

Global:

prosign


nCounter

Nasal Swa


- Multiple-product menu on nCounter drives global expansion
 - Envisia Classifier (2021)
 - Nasal Swab Classifier (2022)
 - Prosigna breast cancer prognostic

® Veracyte, Inc. All rights reserved. CONFIDENTIAL


5-10 Years: Global Market, Menu and Margin Expansion



Proprietary Science and Technology Platform Powers Menu Expansion and Global Commercial Flexibility




New Oncology Indications Drive Pipeline and Enhance Biopharma Partnership Opportunities



>\$40B Global TAM Opportunity

				New Disease Areas	Future Potential
	Thyroid Cancer	IPF	Lung Cancer	Breast Cancer/ Lymphoma	Lung Cancer
Clinical Question	Diagnosis & Therapy Selection	Diagnosis	Risk-Assessment & Diagnosis (Post-CT Scan)	Prognosis & Therapy Selection	Early Detection (Pre-CT Scan)
Product	Afirma GSC/ Xpression Atlas	Envisia Classifier	Nasal Swab Classifier/ Percepta	Prosigna/ LymphMark	Future Nasal Test
US & EU Market	\$800M	\$700M	\$4.4B	>\$1.5B	>\$16.5B
Rest of World	TBD	TBD	>\$1.0B	TBD	>\$20B

Long-Term Revenue Growth Fueled by Addressing Larger Markets



Financial Summary

Consideration

Operational • Supply and service for nCounter system and supply of test kits • Transfer of certain employees to Veracyte Impact • No change to 2019 guidance; continue to expect operating cash flow breakeven be of 2019	consideration	
 Supply and service for nCounter system and supply of test kits Transfer of certain employees to Veracyte Impact No change to 2019 guidance; continue to expect operating cash flow breakeven be of 2019 Transaction expected to add \$6-8M of revenue in 2020 and be cash flow neutral to 1 		 \$40MM in cash \$10MM in Veracyte stock
 Transfer of certain employees to Veracyte Impact No change to 2019 guidance; continue to expect operating cash flow breakeven be of 2019 Transaction expected to add \$6-8M of revenue in 2020 and be cash flow neutral to be cash flow neutral to	Operational	
Impact No change to 2019 guidance; continue to expect operating cash flow breakeven be of 2019 Transaction expected to add \$6-8M of revenue in 2020 and be cash flow neutral to 1 		 Supply and service for nCounter system and supply of test kits
 No change to 2019 guidance; continue to expect operating cash flow breakeven be of 2019 Transaction expected to add \$6-8M of revenue in 2020 and be cash flow neutral to be		Transfer of certain employees to Veracyte
 of 2019 Transaction expected to add \$6-8M of revenue in 2020 and be cash flow neutral to 1 	Impact	
		ne change to ze le guidance, continue to expect operating each new preakeren perere en

